BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 19
• 20
• 21
• 22
• 23
• 24
• 26
• 27
• 28
• 29
• 30

• 

  Pharm Country

  Late-Stage Life Sciences Investment Firm, Aisling Capital, Closes $280M Fund

  Aisling Capital today announced the closing of its newest fund, with $280M in committed capital.

  November 2, 2017

   · 

  2 min read
• 

  Drug Development

  FDA Sticks Breakthrough Tag on GlaxoSmithKline’s Blood Cancer Drug

  GSK2857916 is an anti B-cell maturation agent (BCMA) monoclonal antibody-drug conjugate.

  November 2, 2017

   · 

  4 min read
• 

  Business

  aTyr Promotes CMO to CEO

  aTyr Pharma announced that today Sanjay Shukla, M.D., M.S., who joined aTyr Pharma as CMO in March 2016, will succeed John Mendlein, Ph.D., as President and CEO.

  November 2, 2017

   · 

  6 min read
• Business

  ANI Pharma Reports Record Third Quarter and Year-To-Date 2017 Results and Narrows Full Year Guidance

  The Company will host its earnings conference call this morning, November 2, 2017, at 10:30 AM ET. Investors and other interested parties can join the call by dialing (866) 776-8875.

  November 2, 2017

   · 

  33 min read
• Business

  VolitionRx Limited Schedules Third Quarter 2017 Earnings Conference Call and Business Update

  VolitionRX today announced it will host a conference call on Friday, November 10 at 8:30 a.m.

  November 2, 2017

   · 

  3 min read
• Business

  Therapix Biosciences’ Board Chairman, Ascher Shmulewitz, Appointed as Interim CEO

  Therapix has appointed Ascher Shmulewitz, M.D., Ph.D., the Company’s Chairman of the Board of Directors, to the role of Interim CEO, effective immediately.

  November 2, 2017

   · 

  4 min read
• Policy

  Perrigo Announces Tentative FDA Approval for a First-to-File Generic Version of Picato Gel 0.05%

  The submission date of Perrigo’s ANDA matches the first-to-file date posted on FDA’s Paragraph IV Patent Certifications list.

  November 2, 2017

   · 

  4 min read
• Policy

  scPharma Announces FDA Acceptance of NDA for Furoscix (subcutaneous furosemide)

  The NDA for Furoscix has been accepted for filing by the FDA and under the PDUFA, the FDA has set an action date of June 23, 2018.

  November 2, 2017

   · 

  1 min read
• Drug Development

  Biomarck Announces First Patients Treated in Phase II Clinical Trial of BIO-11006 for ARDS

  This trial will evaluate the safety and efficacy of Biomarck’s novel, patented, MARCKS protein inhibitor in a placebo controlled trial where all patients receive mechanical ventilation as standard of care.

  November 2, 2017

   · 

  3 min read
• Drug Development

  Concentric Analgesics Launches CA-008 Clinical Development Program in Post-Surgical Pain

  Results from this clinical trial are expected in the first quarter of 2018.

  November 2, 2017

   · 

  3 min read